Kadimastem has developed
ground-breaking medical applications in regenerative medicine- “off the shelf” cell products
Our unique technology enables us to produce functioning cells differentiated from pluripotent stem cells. The Company focuses on transplanting healthy brain glial cells (Astrocytes) to support the survivability of nerve cells and is currently in the midst of a Phase I/IIa clinical trial on ALS patients using Kdimastem’s proprietary cell product AstroRx®. Results of cohort C of the trial are expected in the first half of 2021.
Type 1 Diabetes & Insulin dependent Diabetes:
Based on our differentiation platform technology, insulin secreting islets (IsletRx) which are comprised of highly purified functional human pancreatic islet cells. IsletRx can be produced in large quantities. IsletRx cells have demonstrated an ability to balance blood sugar levels and maintain normal levels over time in immunocompetent diabetic mice in our preclinical proof-of-concept study.
Stem Cells Overview
Stem cell therapy is emerging as a new paradigm for treating and potentially curing human neurodegenerative diseases. It involves the use of stem cell-derived living cells to replace and initiate the production of other cells that are missing or damaged due to disease or injury. At the moment, millions of patients are suffering from a wide range of neurodegenerative diseases
Stem cells are defined by two important characteristics: They are able to renew themselves through cell division, and, under certain physiological or experimental conditions, they can differentiate into (turn to) tissue or organ specific cells. In some organs, such as the gut and bone marrow, stem cells often repair and replace damaged tissues. In other organs, such as the pancreas and the heart, stem cells only rarely divide.
4-5 days after fertilization, the pre-embryo, called blastocyst, has an inner mass of cells that can give rise to any cell type (except the placenta).
Human embryonic stem cells (hESC) lines are derived from this inner cell mass. These cells are called pluripotent due to their potency to differentiate into many (pluri) cell types.
Induced pluripotent stem cells (iPSC) are pluripotent stem cells that are artificially made from “regular” adult cells (for example: a skin cell). Inserting specific genes into a cell can cause a the cell to become pluripotent. iPSC share many similar characteristics with hESC, among them unlimited proliferation potential and the ability to differentiate to all the cell types comprising the body. Kadimastem uses both pluripotent cell sources (hESC and iPSC) for deriving its differentiated cells.
Collectively these cells are called human pluripotent stem cells (hPSCs).
1. Izrael M, Slutsky SG, Admoni T, Cohen L, Granit A, Hasson A, et al. Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1(G93A) and NSG animal models. Stem cell research & therapy. 2018;9(1):152.
2. Izrael Michal, Slutsky Shalom Guy, Joseph Itskovitz-Eldor and Revel Michel (December 27th 2017). Astrocytes in Pathogenesis of ALS Disease and Potential Translation into Clinic, Astrocyte, Maria Teresa Gentile and Luca Colucci D’Amato, IntechOpen, DOI: 10.5772/intechopen.72862.
3. Izrael M, Zhang P, Kaufman R, Shinder V, Ella R, Amit M, et al. Human oligodendrocytes derived from embryonic stem cells: Effect of noggin on phenotypic differentiation in vitro and on myelination in vivo. Molecular and cellular neurosciences. 2007;34(3):310-23.